tetano
Editor, Senior Moderator
Open Forum Infect Dis. 2020 Apr 15;7(4)
faa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).
Pastick KA[SUP]1[/SUP], Okafor EC[SUP]1[/SUP], Wang F[SUP]2[/SUP], Lofgren SM[SUP]1[/SUP], Skipper CP[SUP]1[/SUP], Nicol MR[SUP]2[/SUP], Pullen MF[SUP]1[/SUP], Rajasingham R[SUP]1[/SUP], McDonald EG[SUP]3[/SUP], Lee TC[SUP]3[/SUP], Schwartz IS[SUP]4[/SUP], Kelly LE[SUP]5[/SUP], Lother SA[SUP]6[/SUP], Mitj? O[SUP]7[/SUP], Letang E[SUP]8,[/SUP][SUP]9[/SUP], Abassi M[SUP]1[/SUP], Boulware DR[SUP]1[/SUP].
Author information
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
? The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
KEYWORDS:
COVID-19; Hydroxychloroquine; SARS-CoV-2; chloroquine; clinical trials; coronavirus
PMID:32363212PMCID:PMC7184359DOI:10.1093/ofid/ofaa130
faa130. doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).
Pastick KA[SUP]1[/SUP], Okafor EC[SUP]1[/SUP], Wang F[SUP]2[/SUP], Lofgren SM[SUP]1[/SUP], Skipper CP[SUP]1[/SUP], Nicol MR[SUP]2[/SUP], Pullen MF[SUP]1[/SUP], Rajasingham R[SUP]1[/SUP], McDonald EG[SUP]3[/SUP], Lee TC[SUP]3[/SUP], Schwartz IS[SUP]4[/SUP], Kelly LE[SUP]5[/SUP], Lother SA[SUP]6[/SUP], Mitj? O[SUP]7[/SUP], Letang E[SUP]8,[/SUP][SUP]9[/SUP], Abassi M[SUP]1[/SUP], Boulware DR[SUP]1[/SUP].
Author information
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
? The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
KEYWORDS:
COVID-19; Hydroxychloroquine; SARS-CoV-2; chloroquine; clinical trials; coronavirus
PMID:32363212PMCID:PMC7184359DOI:10.1093/ofid/ofaa130